Literature DB >> 17689258

Generation of human innate immune responses towards membrane macrophage colony stimulating factor (mM-CSF) expressing U251 glioma cells within immunodeficient (NIH-nu/beige/xid) mice.

Christina Delgado1, Neil Hoa, Linda L Callahan, Patric M Schiltz, Reza Alipanah Jahroudi, Jian Gang Zhang, H Terry Wepsic, Martin R Jadus.   

Abstract

The response of human peripheral blood mononuclear cells (PBMC) to cloned human HLA-A2+ U251 glioma cells (U251-2F11/TK) expressing membrane macrophage colony stimulating factor (mM-CSF) was investigated in vitro and in vivo. Enriched human monocytes derived from cancer patients produced a respiratory burst following 20min of interaction with mM-CSF expressing U251 glioma cells. This respiratory burst response was not observed in the enriched human monocytes following similar exposure to the viral vector control U251 (U251-VV) cells. Reactive oxygen species such as H(2)O(2) and HOCl produced death of the U251 cells. The U251-2F11/TK cells failed to grow in severely compromised combined immunodeficient (NIH-bg-nu-xidBR) mice that were depleted of murine monocyte/macrophages then reconstituted with human HLA-A2+ PBMC. Reactive oxygen species (ROS) were produced by PBMC, both in vitro and in vivo in response tomM-CSF expressing U251 cells. U251-2F11/TK cells failed to form subcutaneous tumors in macrophage depleted mice reconstituted with human PBMC; whereas, progressive growth of such tumors was observed with the U251-VV cells. U251-2F11/TK tumors formed if the initial inoculums of PBMC were depleted of monocytes. From this work it can be concluded that mM-CSF transduced U251-2F11/TK glioma cells can safely stimulate human innate immune responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689258     DOI: 10.1016/j.cyto.2007.06.003

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  4 in total

Review 1.  Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy.

Authors:  Lisheng Ge; Neil T Hoa; Zechariah Wilson; Gabriel Arismendi-Morillo; Xiao-Tang Kong; Rajeev B Tajhya; Christine Beeton; Martin R Jadus
Journal:  Int Immunopharmacol       Date:  2014-07-12       Impact factor: 4.932

Review 2.  Immunotherapy of brain cancers: the past, the present, and future directions.

Authors:  Lisheng Ge; Neil Hoa; Daniela A Bota; Josephine Natividad; Andrew Howat; Martin R Jadus
Journal:  Clin Dev Immunol       Date:  2011-03-08

Review 3.  Immunological considerations of modern animal models of malignant primary brain tumors.

Authors:  Michael E Sughrue; Isaac Yang; Ari J Kane; Martin J Rutkowski; Shanna Fang; C David James; Andrew T Parsa
Journal:  J Transl Med       Date:  2009-10-08       Impact factor: 5.531

4.  Molecular mechanisms of paraptosis induction: implications for a non-genetically modified tumor vaccine.

Authors:  Neil Hoa; Michael P Myers; Thomas G Douglass; Jian Gang Zhang; Christina Delgado; Lara Driggers; Linda L Callahan; Gerald VanDeusen; Jimmy T H Pham; Nirav Bhakta; Lisheng Ge; Martin R Jadus
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.